#United States #Class Action #Berkeley #Settlement #BeautyHealth

Proposed Class Action Settlement Overview

In a significant development for investors, Hagens Berman Sobol Shapiro LLP has announced a proposed class action settlement involving The Beauty Health Company, commonly referred to as BeautyHealth. This settlement pertains to individuals and entities who acquired BeautyHealth common stock or call options or who sold put options during a specified period between May 10, 2022, and November 13, 2023.

Details of the Settlement

The United States District Court for the Central District of California is set to hear the proposed settlement on December 9, 2026. The hearing, presided over by Honorable Sherilyn Peace Garnett, will address key considerations:
1. Approval of an $18 million cash settlement as fair and adequate for affected class members.
2. Certification of the settlement class.
3. Dismissal of the action following the settlement approval.
4. Consideration of the proposed plan for distributing the settlement amount.
5. Review of attorney fees and expenses, which could amount to up to $5.4 million.
6. Finalizing the judgment for the case.

The action has already been preliminarily certified as a class action, aiming to represent all individuals who purchased BeautyHealth securities or engaged in related transactions during the set period.

Allegations Against BeautyHealth

Allegations against the defendants, including BeautyHealth's executives Andrew Stanleick and Liyuan Woo, center on claims of misleading statements made during the securities transaction period, in violation of the Securities Exchange Act of 1934. Plaintiffs assert that these actions caused the stock prices to be artificially inflated prior to a significant drop related to a corrective disclosure on November 13, 2023. Despite the claims, BeautyHealth has firmly denied any wrongdoing or liability.

Mediation and Resolution Efforts

The settlement was reached after extensive negotiations facilitated by a professional mediator, highlighting the complexities of the case. After submitting detailed mediation statements, discussions culminated in an agreement to settle for $18 million, which echoes the plaintiffs' concerns while minimizing the risk and duration of further litigation.

Financial Implications of the Settlement

Participants in the settlement could see a net recovery estimated to be at least $12 million after accounting for potential attorney fees, litigation costs, and expenses associated with notice and administration. Each class member will need to submit a Proof of Claim to be eligible for recovery, with submissions due by January 19, 2027. Failure to file may result in losing the right to any settlement benefits.

Important Dates and Actions

To ensure participation in this settlement, affected individuals will need to carefully attend to the upcoming deadlines:

• - Hearing Date: December 9, 2026.
• - Proof of Claim Deadline: January 19, 2027.
• - Exclusion Request Deadline: November 24, 2026, for those wishing to opt out of the settlement.

Objections regarding any settlement aspects must also be submitted by November 24, 2026. Those who wish to contest any element of the approved plan, including the allocation and attorney fees, must do so formally.

If you're a class member, staying informed about your rights and actions is critical. It's essential to explore detailed notices and possibly seek legal guidance to navigate this process effectively.

Conclusion

This proposed settlement represents a vital step for numerous investors affected by the alleged misrepresentation by The Beauty Health Company. As the hearing date approaches, potential claimants should proactively gather required documentation, mark their calendars for key deadlines, and remain engaged with follow-up communications.

For more information, affected parties can visit the settlement website or contact their legal representatives for assistance.